Assembly Biosciences (ASMB) EBIT Margin (2017 - 2025)
Historic EBIT Margin for Assembly Biosciences (ASMB) over the last 8 years, with Q3 2025 value amounting to 100.87%.
- Assembly Biosciences' EBIT Margin rose 591900.0% to 100.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 116.83%, marking a year-over-year increase of 471200.0%. This contributed to the annual value of 159.26% for FY2024, which is 7432400.0% up from last year.
- Assembly Biosciences' EBIT Margin amounted to 100.87% in Q3 2025, which was up 591900.0% from 115.24% recorded in Q2 2025.
- In the past 5 years, Assembly Biosciences' EBIT Margin ranged from a high of 100.87% in Q3 2025 and a low of 301.81% during Q3 2021
- Over the past 4 years, Assembly Biosciences' median EBIT Margin value was 156.75% (recorded in 2024), while the average stood at 160.44%.
- Its EBIT Margin has fluctuated over the past 5 years, first tumbled by -2901900bps in 2021, then skyrocketed by 799200bps in 2025.
- Assembly Biosciences' EBIT Margin (Quarter) stood at 301.81% in 2021, then soared by 42bps to 175.22% in 2023, then grew by 11bps to 156.75% in 2024, then skyrocketed by 36bps to 100.87% in 2025.
- Its last three reported values are 100.87% in Q3 2025, 115.24% for Q2 2025, and 105.54% during Q1 2025.